GlassScriptPhysician profile
Michael David Henry
NPI 1346694163
$4,519.83
in general payments reported to CMS, 2019-2025
22 companies · $728 in 2025
The $728 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $94.36 · 2021: $274 · 2022: $1,689 · 2023: $570 · 2024: $792 · 2025: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,089.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $1,100.00 | 2022 | |
| Abbvie INC. | $840.73 | 2022-2025 | |
| Glaukos Corporation | $479.97 | 2022-2025 | Idose, Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
| Alcon Vision LLC | $277.28 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $189.74 | 2020-2022 | |
| Rxsight INC | $171.96 | 2022-2025 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Johnson & Johnson Surgical Vision, INC. | $170.67 | 2022-2025 | Tecnis Iol, Veritas Vision System, Tecnis Simplicity |
| Bausch & Lomb Americas INC. | $147.43 | 2022-2025 | Vyzulta, Prolensa, Envista Mx60 Iol |
| Carl Zeiss Meditec USA, INC. | $145.00 | 2024 | Humphrey Hfa |
| Allergan, INC. | $125.00 | 2021 | |
| Apellis Pharmaceuticals, INC. | $120.18 | 2025 | Syfovre |
| Lantheus Medical Imaging, INC. | $102.22 | 2019-2020 | |
| Oyster Point Pharma, INC. | $97.38 | 2023 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $96.96 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $90.89 | 2024 | Veritas Vision System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $86.79 | 2021-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $71.56 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $64.55 | 2025 | |
| Abbott Laboratories | $57.63 | 2019 | |
| Harrow Eye, LLC | $50.22 | 2024-2025 | Vevye, Flarex, Verkazia |
| Eyevance Pharmaceuticals LLC | $19.17 | 2022 | |
| Akorn Operating Company LLC | $14.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.